Literature DB >> 22914366

Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.

Ellen S Vitetta1, Joan E Smallshaw, John Schindler.   

Abstract

There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22914366      PMCID： PMC3485895          DOI： 10.1128/CVI.00381-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  18 in total

Review 1.  Overview of vaccine adjuvants: present and future.

Authors:  Robert L Hunter
Journal:  Vaccine       Date:  2002-05-31       Impact factor: 3.641

Review 2.  The history of ricin, abrin and related toxins.

Authors:  Sjur Olsnes
Journal:  Toxicon       Date:  2004-09-15       Impact factor: 3.033

3.  A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.

Authors:  D Castelletti; G Fracasso; S Righetti; G Tridente; R Schnell; A Engert; M Colombatti
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

4.  Structure of ricin B-chain at 2.5 A resolution.

Authors:  E Rutenber; J D Robertus
Journal:  Proteins       Date:  1991

5.  Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells.

Authors:  K Eiklid; S Olsnes; A Pihl
Journal:  Exp Cell Res       Date:  1980-04       Impact factor: 3.905

6.  Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones.

Authors:  M Tommasi; D Castelletti; M Pasti; G Fracasso; I Lorenzetti; S Sartoris; C Pera; G B Ferrara; G Tridente; M Colombatti
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

7.  Site-directed mutagenesis of ricin A-chain and implications for the mechanism of action.

Authors:  M P Ready; Y Kim; J D Robertus
Journal:  Proteins       Date:  1991

Review 8.  Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence.

Authors:  Tom Jefferson; Melanie Rudin; Carlo Di Pietrantonj
Journal:  Lancet Infect Dis       Date:  2004-02       Impact factor: 25.071

9.  A novel recombinant vaccine which protects mice against ricin intoxication.

Authors:  Joan E Smallshaw; Ana Firan; John R Fulmer; Stephen L Ruback; Victor Ghetie; Ellen S Vitetta
Journal:  Vaccine       Date:  2002-09-10       Impact factor: 3.641

10.  Structure of RiVax: a recombinant ricin vaccine.

Authors:  Patricia M Legler; Robert N Brey; Joan E Smallshaw; Ellen S Vitetta; Charles B Millard
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-08-09
View more
  28 in total

1.  Recent advances in the development of vaccines against ricin.

Authors:  Robert N Brey; Nicholas J Mantis; Seth H Pincus; Ellen S Vitetta; Leonard A Smith; Chad J Roy
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

2.  Toxicity of ricin A chain is reduced in mammalian cells by inhibiting its interaction with the ribosome.

Authors:  Amanda E Jetzt; Xiao-Ping Li; Nilgun E Tumer; Wendie S Cohick
Journal:  Toxicol Appl Pharmacol       Date:  2016-09-15       Impact factor: 4.219

3.  Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.

Authors:  Joanne M O'Hara; Robert N Brey; Nicholas J Mantis
Journal:  Clin Vaccine Immunol       Date:  2013-03-20

4.  Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen.

Authors:  Justin C Thomas; Joanne M O'Hara; Lei Hu; Fei P Gao; Sangeeta B Joshi; David B Volkin; Robert N Brey; Jianwen Fang; John Karanicolas; Nicholas J Mantis; C Russell Middaugh
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

5.  Crystal structures of ricin toxin's enzymatic subunit (RTA) in complex with neutralizing and non-neutralizing single-chain antibodies.

Authors:  Michael J Rudolph; David J Vance; Jonah Cheung; Matthew C Franklin; Fiana Burshteyn; Michael S Cassidy; Ebony N Gary; Cristina Herrera; Charles B Shoemaker; Nicholas J Mantis
Journal:  J Mol Biol       Date:  2014-06-04       Impact factor: 5.469

6.  High-Resolution Epitope Positioning of a Large Collection of Neutralizing and Nonneutralizing Single-Domain Antibodies on the Enzymatic and Binding Subunits of Ricin Toxin.

Authors:  David J Vance; Jacqueline M Tremblay; Yinghui Rong; Siva Krishna Angalakurthi; David B Volkin; C Russell Middaugh; David D Weis; Charles B Shoemaker; Nicholas J Mantis
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

7.  Alpha-galactosylceramide (αGalCer) enhances vaccine-induced protection in a model of ricin intoxication.

Authors:  Jennifer L Yates; Elizabeth Leadbetter; Nicholas J Mantis
Journal:  Hum Vaccin Immunother       Date:  2018-05-14       Impact factor: 3.452

8.  Novel Ricin Subunit Antigens With Enhanced Capacity to Elicit Toxin-Neutralizing Antibody Responses in Mice.

Authors:  Newton Wahome; Erin Sully; Christopher Singer; Justin C Thomas; Lei Hu; Sangeeta B Joshi; David B Volkin; Jianwen Fang; John Karanicolas; Donald J Jacobs; Nicholas J Mantis; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2016-03-15       Impact factor: 3.534

9.  Neutralizing monoclonal antibodies against ricin's enzymatic subunit interfere with protein disulfide isomerase-mediated reduction of ricin holotoxin in vitro.

Authors:  Joanne M O'Hara; Nicholas J Mantis
Journal:  J Immunol Methods       Date:  2013-06-15       Impact factor: 2.303

Review 10.  Progress and challenges associated with the development of ricin toxin subunit vaccines.

Authors:  David J Vance; Nicholas J Mantis
Journal:  Expert Rev Vaccines       Date:  2016-04-06       Impact factor: 5.217
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.